Diffuse lung involvement in rheumatoid arthritis:a respiratory physician’s perspective  

作　　者：Hui Huang Ruxuan Chen Chi Shao Zuojun Xu Paul J.Wolters 

机构地区：[1]Department of Pulmonary and Critical Care Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China [2]Department of Pulmonary and Critical Care Medicine,University of California,San Francisco,CA 94117,USA

出　　处：《Chinese Medical Journal》2023年第3期280-286,共7页中华医学杂志（英文版）

基　　金：supported by the National High Level Hospital Clinical Research Funding(No.2022-PUMCHA-009);the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(No.2019XK320037).

摘　　要：The lungs are one of the most common extra-articular organs involved in rheumatoid arthritis(RA),which is reported to occur in up to 60%to 80%of RA patients.Respiratory complications are the second leading cause of death due to RA.Although there is a wide spectrum of RA-associated respiratory diseases,interstitial lung disease is the most common manifestation and it impacts the prognosis of RA.There has been progress in understanding the management and progression of rheumatoid arthritis-associated interstitial lung disease(RA-ILD)and RA-associated respiratory diseases recently,for example,opportunistic pulmonary infectious diseases and toxicity from RA therapies.From a chest physicians’perspective,we will update the diagnosis and treatment of RA-associated ILD,methotrexate-associated lung disease,and the complication of Pneumocystis jiroveci pneumonia in RA in this review.

关 键 词：Interstitial lung disease Lung Methotrexate pneumonitis Pneumocystis jiroveci pneumonia Rheumatoid arthritis 

分 类 号：R593.22[医药卫生—内科学] R563[医药卫生—临床医学]